Announcement on Voluntary Disclosure on Phase II Clinical Trial Data of Oral APL-1202 Combined with Tislelizumab in Neoadjuvant Therapy for Muscle-invasive Bladder Cancer at the 2025 American Society of Clinical Oncology (ASCO) Genitourinary Cancer Symposium
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
View Attachment
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
View Attachment